Horizon Therapeutics (Horizon Therapeutics) 3-Year Revenue Growth Rate : 34.50% (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Horizon Therapeutics 3-Year Revenue Growth Rate?

Horizon Therapeutics's Revenue per Share for the three months ended in Jun. 2023 was $4.04.

During the past 12 months, Horizon Therapeutics's average Revenue per Share Growth Rate was -3.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 34.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 21.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 32.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Horizon Therapeutics was 115.50% per year. The lowest was -9.90% per year. And the median was 22.85% per year.

Competitive Comparison of Horizon Therapeutics's 3-Year Revenue Growth Rate

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Horizon Therapeutics's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's 3-Year Revenue Growth Rate falls into.

Horizon Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Horizon Therapeutics (NAS:HZNP) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Horizon Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Horizon Therapeutics (Horizon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (NAS:HZNP) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

70 St. Stephen’s Green, Dublin, IRL, D02 E2X4

Website

https://www.horizontherapeutics.com

Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Executives

Andy Pasternak	officer: EVP and Chief Business Officer	C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN L2 D04 C5Y6
Aaron Cox	officer: EVP, Chief Financial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Jeffrey W Sherman	officer: EVP & Chief Medical Officer	C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Patrick Mcilvenny	officer: Chief Accounting Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Sean M. Clayton	officer: EVP, General Counsel	C/O HORIZON THERAPEUTICS PLC, 70 SAINT STEPHENS GREEN, DUBLIN L2 D02 E2X4
Thompson Elizabeth H.z.	officer: EVP, Research & Development	C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert	director, officer: President, Chairman and CEO	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Jacopo Leonardi	officer: Chief Commercial Officer	C/O HORIZON THERAPEUTICS PLC, 70 ST. STEPHEN'S GREEN, DUBLIN L2 D02 E2X4
Paul W. Hoelscher	officer: EVP Finance	1 HORIZON WAY, C/O HORIZON THERAPEUTICS, INC., DEERFIELD IL 60015
Michael A. Desjardin	officer: EVP, Technical Operations	C/O JAZZ PHARMACEUTICALS, INC., 3180 PORTER DRIVE, PALO ALTO CA 94304
Miles W Mchugh	officer: Principal Accounting Officer	C/O ACCRETIVE HEALTH, INC., 401 N. MICHIGAN AVE, SUITE 2700, CHICAGO IL 60611
Barry Moze	officer: EVP, Corporate Dev't.	C/O HORIZON PHARMA, INC., 520 EAST COOK ROAD, SUITE 520, DEERFIELD IL 60015
Brian K Beeler	officer: EVP, General Counsel	C/O HORIZON PHARMA PLC, 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60015
Michael G Grey	director	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
William F Daniel	director	TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000